METAGENOMI INC (MGX) Stock Price, Forecast & Analysis
USA - NASDAQ:MGX - US59102M1045 - Common Stock
MGX Key Statistics, Chart & Performance
The current stock price of MGX is 2.22 USD. In the past month the price decreased by -29.15%. In the past year, price increased by 11.88%.
MGX Latest News, Press Relases and Analysis
MGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.02 | 384.26B | ||
| AMGN | AMGEN INC | 14.43 | 169.85B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 153.30B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.96 | 106.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.49 | 69.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 858.59 | 57.40B | ||
| ARGX | ARGENX SE - ADR | 63.67 | 52.57B | ||
| INSM | INSMED INC | N/A | 39.37B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.55 | 37.72B | ||
| NTRA | NATERA INC | N/A | 27.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.70B | ||
| BIIB | BIOGEN INC | 9.26 | 22.72B |
Related stock screener links
About MGX
Company Profile
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 171 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The firm uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Company Info
METAGENOMI INC
5959 Horton St, Floor 7
Emeryville CALIFORNIA US
Employees: 171
Phone: 15108714880
METAGENOMI INC / MGX FAQ
Can you describe the business of METAGENOMI INC?
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 171 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The firm uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Can you provide the latest stock price for METAGENOMI INC?
The current stock price of MGX is 2.22 USD. The price decreased by -1.77% in the last trading session.
Does MGX stock pay dividends?
MGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of MGX stock?
MGX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about METAGENOMI INC (MGX) stock?
9 analysts have analysed MGX and the average price target is 10.2 USD. This implies a price increase of 359.46% is expected in the next year compared to the current price of 2.22.
What is the GICS sector and industry of MGX stock?
METAGENOMI INC (MGX) operates in the Health Care sector and the Biotechnology industry.
How many employees does METAGENOMI INC have?
METAGENOMI INC (MGX) currently has 171 employees.
MGX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MGX. When comparing the yearly performance of all stocks, MGX is one of the better performing stocks in the market, outperforming 79.18% of all stocks.
MGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGX. MGX has a great financial health rating, but its profitability evaluates not so good.
MGX Financial Highlights
Over the last trailing twelve months MGX reported a non-GAAP Earnings per Share(EPS) of -2.36. The EPS increased by 6.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32% | ||
| ROE | -44.49% | ||
| Debt/Equity | 0 |
MGX Forecast & Estimates
9 analysts have analysed MGX and the average price target is 10.2 USD. This implies a price increase of 359.46% is expected in the next year compared to the current price of 2.22.
For the next year, analysts expect an EPS growth of 7.71% and a revenue growth -47.29% for MGX